help button home button Endocrine Society JCEM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Submit a related Letter to the Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Cundiff, J. G.
Right arrow Articles by Prabhakar, B. S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Cundiff, J. G.
Right arrow Articles by Prabhakar, B. S.
The Journal of Clinical Endocrinology & Metabolism Vol. 86, No. 9 4254-4260
Copyright © 2001 by The Endocrine Society

Other Original Articles

Studies Using Recombinant Fragments of Human TSH Receptor Reveal Apparent Diversity in the Binding Specificities of Antibodies That Block TSH Binding to Its Receptor or Stimulate Thyroid Hormone Production

Jason G. Cundiff, Shashi Kaithamana, Gattadahalli S. Seetharamaiah, James R. Baker, Jr. and Bellur S. Prabhakar

Department of Microbiology and Immunology, University of Illinois College of Medicine (J.G.C., S.K., B.S.P.), Chicago, Illinois 60612; Indiana University School of Medicine (G.S.S.), Evansville, Indiana 47712; and University of Michigan (J.R.B.), Ann Arbor, Michigan 48109

Address all correspondence and requests for reprints to: Dr. Bellur S. Prabhakar (MC 790), Department of Microbiology and Immunology, E-705 Medical Sciences Building, 835 South Wolcott Avenue, Chicago, Illinois 60612.

Abstract

Patients with Graves’ disease have autoantibodies that bind to the TSH receptor and stimulate the thyroid, leading to hyperthyroidism. Earlier studies have shown that the ectodomain of the glycosylated human TSH receptor contains epitopes that could adsorb these pathogenic antibodies. Further studies with mutated cDNAs, chimeric proteins, peptides, and antipeptide antibodies suggested that alterations in the conformation of the protein could lead to loss of reactivity, and that thyroid-stimulating antibodies interact with the N-terminal region of the TSH receptor. Although many of these studies provided valuable insights, they were somewhat inconclusive due to limitations inherent to each of the approaches. In an attempt to further define regions within the TSH receptor with which thyroid-stimulating antibodies interact, we expressed seven recombinant TSH receptor fragments in insect cells and tested them for their ability to neutralize TSH binding inhibitory Igs and thyroid-stimulating antibody activity in the sera of patients with Graves’ disease. The fragments containing amino acids 22–305 were able to neutralize the TSH binding inhibitory Ig activity, whereas a fragment containing amino acids 54–254 was able to neutralize the thyroid-stimulating antibodies. Fragments containing additional amino acids, flanking residues 54–254, failed to neutralize the thyroid-stimulating antibody activity, suggesting that thyroid-stimulating antibody epitopes are masked. Our studies show that thyroid autoantibodies, with different functional properties, bind to distinct conformational epitopes on the TSH receptor.

THE TSH RECEPTOR (TSHR) is an important autoantigen in many autoimmune thyroid diseases, including Graves’ disease (GD) (reviewed in Refs. 1, 2, 3, 4). GD is characterized by the presence of thyroid-stimulating antibodies (TSAb). The TSAb bind to the TSHR and mimic the action of TSH, leading to hyperthyroidism. Cloning and sequencing of a cDNA encoding the human TSHR showed that it consists of 764 amino acids (aa) with a 415-aa extracellular domain containing six potential glycosylation sites, seven hydrophobic membrane spanning domains, and one cytoplasmic domain (5, 6, 7, 8, 9, 10). Several laboratories, including our own, have shown that the ectodomain of TSHR (ETSHR) is sufficient for TSH and TSAb binding (11, 12, 13, 14, 15, 16, 17). Earlier studies had shown that glycosylated ETSHR (ETSHR-gp) is necessary for reactivity with TSAb (15, 16). Moreover, studies using mutagenesis of TSHR, synthetic peptides, and chimeric proteins (TSHR/LH-CGr) have indicated that TSAb bind to the N-terminal region of the ETSHR (reviewed in Refs. 1, 2, 3, 4). However, in many instances these studies were unable to account for either lack of native conformation or glycosylation due to limitations inherent to each of the approaches. Therefore, the objective of the current study was to use the predicted structural information (18) to design and generate recombinant fragments of ETSHR-gp and identify functional domains to which TSAb bind.

Materials and Methods

Source of sera

Sera were collected from patients with GD. Diagnoses were based on appropriate standard clinical and laboratory criteria. From the GD sera collected, seven sera, from patients designated 1–7, were selected based on their elevated thyroid receptor antibody [TSH binding inhibitory Ig (TBII)] values (Fig. 4Go, graph A). The TBII values were determined using a commercially available TBII assay (Kronus, Dana Point, CA). Sera were also obtained from healthy volunteers with no family history of autoimmune thyroid disease. Sera were stored at -20 C until used.



View larger version (47K):
[in this window]
[in a new window]
  		Figure 4. Inhibition of TBII by ETSHR-gp and various ETSHR fragments 1–7. The ability of ETSHR-gp or ETSHR fragments 1–7 to neutralize the TBII activity in GD patients was assessed using RRA. Graph A represents the TRAb values of patients’ sera tested. Graphs B–H represent the inhibition of TBII activity in patients’ sera 1–7, respectively. As shown, only ETSHR-gp, fragments 2 and 3, were able to neutralize the TBII activity.

 
Cell culture

Sf9 insect cells (Life Technologies, Inc., Gaithersburg, MD) were maintained in TNM-FH medium (Sigma, St. Louis, MO) supplemented with 10% FBS (Sigma) and antibiotic/antimycotic agents.

Construction of transfer vector

Results from computer modeling were used to design seven recombinant ETSHR-gp fragments in which structural conformation was likely to be maintained (18). The primers used to generate the corresponding cDNA fragments, and the outlines of these fragments are shown in Figs. 1Go and 2Go, respectively. Using ETSHR cDNA as the template and appropriate sense and antisense primers, seven cDNAs (ETSHR fragments 1–7) were created employing PCR. The cDNAs encoding ETSHR fragments 1–7 were cloned in the proper orientation into the unique EcoRI site of the transfer vector pAcGP67A (PharMingen, San Diego, CA).



View larger version (33K):
[in this window]
[in a new window]
  		Figure 1. Primers for generating ETSHR fragments 1–7. The underlined nucleotides of the primers represent an EcoRI restriction site. The antisense primers have a stop codon following the restriction site. The numbers in parentheses represent nucleic acid residue numbers of the ETSHR cDNA sequence.

 


View larger version (17K):
[in this window]
[in a new window]
  		Figure 2. Amino acid regions of ETSHR- gp and ETSHR fragments 1–7. Shown are the amino acids contained in the recombinant fragments produced for this study.

 
Generation of recombinant baculoviruses

Seven different recombinant viruses were generated by cotransfecting Sf9 cells with 0.5 µg linearized Baculogold viral DNA (PharMingen) and 2 µg pAcGP67A DNA containing a cDNA encoding each of the seven ETSHR fragments according to the manufacturer’s protocol. Media containing the recombinant viruses were harvested after 5 d and amplified twice to obtain higher titers of virus. Amplification occurs via infecting monolayers of Sf9 cells with previously harvested medium. The media from this reinfection was harvested after 5 d and stored at -20 C. This amplification process increases the viral titers found in the medium. Generation of recombinant ETSHR-gp virus has been described previously (16).

Expression of ETSHR fragments 1–7 and ETSHR-gp

For recombinant protein production we followed a previously published protocol (13). Monolayers of Sf9 cells were infected with ETSHR 1–7 or ETSHR-gp viruses. Cells were harvested, and proteins were separated by SDS-PAGE and either stained with Coomassie blue or subjected to Western blot analysis. For Western blotting, proteins separated by SDS-PAGE were electrophorectically transferred onto nitrocellulose membranes and stained with ETSHR-gp-specific Abs.

Neutralization of TBII activity in patients’ sera

A modified TBII assay was used to test the ability of ETSHR-gp and ETSHR fragments 1–7 to neutralize the TBII activity in GD patients’ sera (16). Fifty microliters of GD and control sera were incubated for 2 h at room temperature with 3 x 106 insect cells expressing ETSHR-gp, ETSHR fragments 1–7, or uninfected Sf9 cells and then tested for their TBII activity using a commercially available RRA (Kronus). Insect cells (3 x 106) were used in this assay to ensure an excess antigen to antibody ratio.

Neutralization of the biological activity of TSAb in patients’ sera

Chinese hamster ovary (CHO) cells permanently transfected with a full-length human TSHR cDNA were provided by Drs. K Tahara and L. D. Kohn, NIDDK, NIH (Bethesda, MD) (19). The CHO cells expressing TSHR were grown to confluence in 96-well plates. Of the 7 sera originally selected, 4 sera (patients 1–4) possessed elevated TSAb activity based on cAMP assay and were used in this experiment. Ten microliters of GD patients’ sera were incubated with 2 x 106 insect cells expressing ETSHR-gp or ETSHR fragments 1–7 for 1 h at room temperature. Insect cells (2 x 106) were used to ensure an excess antigen to antibody ratio. To test the biological activity of TSAb, sera that were incubated with or without the recombinant proteins were added to duplicate wells in a hypotonic HBSS containing 0.5 mM 3-isobutylmethylxanthine and incubated at 37 C in 5% CO2 for 3 h (16). The final volume in all wells was 100 µl/well. Subsequently, supernatants were collected, diluted 1:20, and assayed for cAMP using a commercially available RIA kit (DuPont, Boston, MA).

Results

Expression of ETSHR fragments 1–7

The Sf9 cells were infected with various recombinant viruses described above and analyzed by SDS-PAGE for the production of recombinant proteins. Figure 3Go shows a Coomassie blue-stained gel and a Western blot analysis of the recombinant proteins. Major protein bands were observed for ETSHR fragments 1–7 at approximately 6, 37, 39, 34, 35, 26, and 22 kDa, respectively. The expected molecular masses for ETSHR fragments 1–7 based on their aa sequence are 5.9, 25.5, 31.1, 22.0, 25.2, 17.7, and 12.2 kDa, respectively. The larger molecular masses observed for ETSHR fragments 2–7 are most likely due to glycosylation, as each of these fragments contains one or more potential glycosylation sites.



View larger version (48K):
[in this window]
[in a new window]
  		Figure 3. Expression of ETSHR fragments 1–7. Shown is a Coomassie blue-stained gel and a Western blot analysis of seven recombinant proteins produced using the baculovirus expression system. The Western blot was stained using an anti-ETSHR-gp antibody. Major protein bands were observed for ETSHR 1–7 at approximately 6, 37, 39, 34, 35, 26, and 22 kDa, respectively. The larger than expected molecular mass observed in ETSHR 2–7 is most likely due to glycosylation of the proteins in insect cells.

 
Neutralization of TBII activity in GD sera

A routinely used commercial RRA measures the ability of antibodies to bind to TSHR on porcine thyroid membrane and block the binding of 125I-labeled TSH. Using this assay, we tested the recombinant proteins for their ability to neutralize autoantibodies to TSHR in the sera of patients with GD. As shown in Fig. 4Go, TBII activity was significantly neutralized with ETSHR-gp. ETSHR fragments 2 and 3 showed varying, but considerable, neutralization of the TBII activities. In contrast, ETSHR fragments 1 and 4–7 failed to neutralize the TBII activities in any of the seven sera tested with the exception of patient 5 with fragment 7. This assay was repeated using patient sera 1 and 2, and similar results were observed.

Neutralization of TSAb activity in GD sera

The TBII assay detects anti-TSHR antibodies that may or may not have biological activities and are not useful for discriminating between blocking (often found in patients with primary myxedema) or stimulatory (found in patients with GD) antibodies. Therefore, we carried out the bioassay to identify fragments to which stimulatory antibodies bind. When CHO cells expressing TSHR were incubated with either TSH or stimulatory antibodies, they produced elevated levels of cAMP. To evaluate ETSHR fragments for their ability to neutralize the TSAb activity, GD patients’ sera were incubated with ETSHR-gp or ETSHR fragments 1–7. Subsequently, these sera were tested for their ability to stimulate cAMP production. As shown in Fig. 5Go, incubation with either ETSHR-gp or ETSHR fragment 4 resulted in maximal neutralization of the TSAb activity in three of four and, to a lesser extent, in one of four sera. These results showed that ETSHR fragment 4 has TSAb-reactive epitopes. It is interesting to note that treatment of sera with ETSHR fragments 1, 5, 6, and 7 enhanced TSAb activity to varying degrees, with ETSHR fragment 7 showing maximal enhancement. This assay was repeated using both patient sera 3 and 4, and similar results were observed.



View larger version (69K):
[in this window]
[in a new window]
  		Figure 5. ETSHR fragments inhibit cAMP induction by patient sera. The ability of ETSHR-gp and ETSHR fragments 1–7 to neutralize the TSAb in GD patients was assessed by RIA. As shown, ETSHR-gp and ETSHR fragment 4 were able to neutralize the TSAb activity in the sera of patients 2–4. In patient serum 1, ETSHR-gp and ETSHR fragments 2, 3, and 4 were able to significantly reduce TSAb activity.

 
Discussion

Many investigators have attempted to finely define the different functional epitopes of TSHR involved in TSH and autoantibody binding and have suggested that TSAb bind to the N-terminal region of the ETSHR (reviewed in Refs. 1, 2, 3, 4). However, in some instances, these studies were unable to account for either lack of native conformation or glycosylation due to limitations inherent to each of the approaches. Therefore, the objective of the current study was to exploit the predicted three-dimensional structure of the TSHR to generate recombinant fragments of the human ETSHR-gp. The fragments were selected for the following reasons. ETSHR fragment 1 was selected because aa 22–76 contained the unique insertion site and preceded the leucine-rich repeat (LRR) domain and the potential glycosylation sites. ETSHR fragment 2 (aa 22–254) consists of the unique insertion site and the LRR. ETSHR fragment 3 (aa 22–305) consists of the unique insertion, LRR domain, and all potential glycosylation sites. ETSHR fragment 4 (aa 54–254) consists of only the LRR domain. ETSHR fragment 5 (aa 76–305) consists of all potential glycosylation sites. ETSHR fragment 6 consists of the post-LLR domain. ETSHR fragment 7 consists of domains present beyond all glycosylation sites and represents the most hydrophilic (thus most immunogenic) region of the ETSHR-gp (18). These fragments are expected to retain their domain conformation and be glycosylated (when glycosylation sites are available). This, we reasoned, would be better than using relatively short synthetic peptides that are not glycosylated and most likely lack conformation. Therefore, the fragments were expressed and employed to identify domains to which TSHR autoantibodies bind.

We expressed ETSHR-gp and seven ETSHR fragments (i.e. ETSHR 1–7; aa 22–76, 22–254, 22–305, 54–254, 76–305, 255–416, and 305–416, respectively) spanning the entire ETSHR-gp. We then tested for their ability to neutralize the TBII activity of GD patients’ sera. As shown previously, ETSHR- gp almost completely neutralized the TBII activity in six of seven sera, and neutralized over 50% in one of seven sera (16, 19). Similarly, ETSHR fragments 2 and 3 were also able to neutralize the TBII activity, but in some cases to a lesser extent than that seen with ETSHR-gp. Although, ETSHR fragment 3 was slightly more effective than ETSHR fragment 2, our results indicate that aa 22–254 may be sufficient to significantly neutralize the TBII activity. These data are in agreement with earlier studies that showed that recombinant TSHR-261 (aa 1–261) and TSHR-289 (aa 1–289) expressed in CHO cells neutralized the TBII activity in the sera of Graves’ patients (20, 21). Our results also suggest that aa 254–305 (present on ETSHR fragment 3 but not on ETSHR fragment 2) provide either additional epitopes or further enhance the conformation required for more effective autoantibody binding.

Interestingly, ETSHR fragment 1 (aa 22–76) did not react with the sera, suggesting that this region is not critical. However, ETSHR fragment 5 (aa 76–305) which is similar to ETSHR fragment 3 (aa 22–305), except that it does not contain aa 22–76, did not react with the sera either. These results suggest that aa 22–76 are essential for appropriate folding of the protein required for the formation of TBII binding epitope(s). Together, our results show that a significant part of the TBII activity is due to interactions with epitopes that reside within aa 22–254 of the human ETSHR-gp.

In our earlier study, using TSHR LH/CGR chimeric proteins, we showed that MC2 and MC2+4 (in which aa 89–164 and aa 89–164, 260–333 of TSHR are replaced with the corresponding aa from LH/CGR, respectively) were able to neutralize TBII activity of patient sera. However, replacement of aa 8–88 (MC1), 165–259 (MC3), or 260–333 (MC4) completely abrogated the ability of the protein to neutralize the TBII activity in patient sera. This would suggest that aa 89–164 are not important for detecting TBII activity (22). Combined with our current results, it would appear that the predominant TBII binding region consists of aa 22–305 (to a lesser extent aa 22–254); however, aa 89–164 within this region do not appear to be critical. Full resolution of this would require structural studies.

Next, we tested the ability of the ETSHR-gp and its fragments to neutralize the ability of TSAb to induce cAMP production. To carry out these studies we selected four different sera containing relatively high levels of TSAb activity (patients 1–4). Both ETSHR-gp and ETSHR fragment 4 were able to neutralize the TSAb activity. This suggested that aa 54–254 represent the core residues containing the epitopes to which TSAb bind. However, ETSHR fragments 2 and 3, which contain all of the amino acids present in ETSHR fragment 4, largely failed to neutralize the TSAb activity. Intuitively, one would have expected these fragments also to neutralize the TSAb activity, but they did not. This raises the possibility that amino acids flanking ETSHR fragment 4 (aa 22–53 present in both ETSHR fragments 2 and 3, and aa 255–305 present in ETSHR fragment 3) somehow obscure the TSAb epitope(s). Other studies using cells transfected with cDNAs encoding TSHR-LH/CGR chimeras have shown that aa 23–165 of human TSHR are important for both TBII and TSAb activities, and aa 90–165 are important for TSAb activity (23, 24, 25, 26, 27, 28, 29, 30). Our current data are in general agreement with these earlier results.

Antigenic sites on a complex protein can be broadly divided into dominant, subdominant, and cryptic epitopes (31, 32, 33, 34). Epitopes against which an immune response can be readily elicited are considered immunodominant. In contrast, induction of an immune response against certain epitopes is very difficult. These regions are considered to be immunologically cryptic, and the remaining epitopes are considered to be subdominant. Usually, immune responses against dominant and subdominant epitopes, but not against cryptic epitopes of self-antigens, can be readily induced in experimental animals. Despite high levels of antibodies against self-antigens (i.e. autoimmunity), these animals show no signs of autoimmune disease. This is the case in mice immunized with different insect cell-derived TSHR preparations. These mice develop very high titers of antibodies with significant TBII activity, but fail to show either severe hyperthyroidism or high levels of TSAbs (35, 36, 37, 38).

It is generally accepted that most pathogenic epitopes on autoantigens are cryptic, and if the immune response directed against dominant epitopes eventually turns against the cryptic epitopes, most likely through immunological repertoire spreading, then the disease ensues. If this were true for the TSHR, then aa 55–254 probably represent an immunologically cryptic region, and by removing surrounding amino acids, this region becomes exposed and is capable of reacting with TSAbs. The presence of flanking residues on the N-terminal side (i.e. aa 22–53 in ETSHR fragments 2 and 3) reduces TSAb reactivity, with this reactivity further abrogated by the presence of additional flanking residues on the C-terminal end of the fragment (i.e. aa 255–305 in ETSHR fragment 3). If this were the case, then how could B cells recognize the cryptic regions and produce TSAbs that can react against intact TSHR in vivo? Although we do not know the answer, a likely explanation is that autoantibodies to TSHR are heterogeneous. Perhaps nonpathogenic antibodies that can bind to some of the dominant epitopes appear first and alter the conformation of the TSHR protein, leading to exposure of cryptic epitopes. This would allow subsequent TSAb production as well as binding.

Recently, we studied the evolution of antibody response against the TSHR in a mouse model for Graves’ disease (39). These studies showed that initially ELISA-positive but TBII-negative Abs appear, followed by the appearance of TBII-positive Abs with subsequent production of TSAbs (39). Evolution of TSAbs could be primarily due to repertoire spreading, although affinity maturation of antibodies can also contribute. Studies are underway to determine which of the two mechanisms is relevant for TSAb production and to see whether one can more readily induce TSAbs in experimental animals using ETSHR fragment 4 relative to other fragments.

Acknowledgments

Footnotes

This work was supported in part by an Alpha Omega Alpha Student Research Fellowship and Grants DK-47417 and DK-44972 from the NIH.

Abbreviations: aa, Amino acid; ETSHR, ectodomain of TSHR; ETSHR-gp, glycosylated ETSHR; GD, Graves’ disease; LRR, leucine-rich repeat; TBII, TSH binding inhibitory Ig; TSHR, TSH receptor; TSAb, thyroid-stimulating antibodies.

Received February 12, 2001.

Accepted May 9, 2001.

References

  1. Rapoport B, Chazenbalk GD, Jaume JC, McLachlan SM 1998 The thyrotropin receptor: interaction with thyrotropin and autoantibodies. Endocr Rev 19: 673–716
  2. Vassart G, Dumont JE 1992 The thyrotropin receptor and the regulation of the thyrocyte function and growth. Endocr Rev 13:596–611[Abstract/Free Full Text]
  3. Kohn LD, Shimura H, Shimura Y, et al. 1995 The thyrotropin receptor. Vitam Horm 50:287–384[Medline]
  4. Prabhakar BS, Fan JL, Seetharamaiah GS 1997 Thyrotropin-receptor-mediated diseases: a paradigm for receptor autoimmunity. Immumol Today 18:437–442[CrossRef][Medline]
  5. Nagayama Y, Kaufman KD, Seto P, Rapoport B 1989 Molecular cloning, sequence and functional expression of the cDNA for the human thyrotropin receptor. Biochem Biophys Res Commun 165:1184–1190[CrossRef][Medline]
  6. Libert F, Lefort A, Gerard C, et al. 1989 Cloning, sequencing and expression of the human thyrotropin (TSH) receptor: evidence for binding of autoantibodies. Biochem Biophys Res Commun 165:1250–1255[CrossRef][Medline]
  7. Parmentier M, Libert F, Maenhaut C, et al. 1989 Molecular cloning of the thyrotropin receptor. Science 246:1620–1622[Abstract/Free Full Text]
  8. Misrahi M, Loosefelt H, Atger M, Sar S, Guichon-Matel A, Milgrom E 1989 Cloning, sequencing and expression of human TSH receptor. Biochem Biophys Res Commun 166:394–403
  9. Akamizu T, Ikuyama S, Saji M, et al. 1990 Cloning, chromosomal assignment, and regulation of the rat thyrotropin receptor: expression of the gene is regulated by thyrotropin, agents that increase cAMP levels, and thyroid autoantibodies. Proc Natl Acad Sci USA 81:5677–5681
  10. Frazier AL, Robbings LS, Stork PJ, Sprengel R, Segaloff DL, Cone RD 1990 Isolation of TSH and LH/CG receptor cDNAs from human thyroid: regulation by tissue specific splicing. Mol Endocrinol 4:1264–1276[Abstract/Free Full Text]
  11. Nagayama Y, Russo D, Chazenbalk GD, Wadsworth HL, Rapoport B 1990 Extracellular domain chimeras of TSH and LH/CG receptors reveal the mid-region (amino acids 171–260) to play a vital role in high affinity TSH binding. Biochem Biophys Res Commun 173:1150–1156[CrossRef][Medline]
  12. Shi Y, Zou M, Parhar RS, Farid NR 1993 High-affinity binding of thyrotropin to the extracellular domain of its receptor transfected in Chinese hamster ovary cells. Thyroid 3:129–133[Medline]
  13. Seetharamaiah GS, Kurosky A, Desai RK, Dallas JS, Prabhakar BS 1994 A recombinant extracellular domain of the thyrotropin (TSH) receptor binds TSH in the absence of membranes. Endocrinology 134:549–554[Abstract/Free Full Text]
  14. Osuga Y, Liang SG, Dallas JS, Wang C, Hsueh AJW 1998 Soluble ectodomain mutant of thyrotropin (TSH) receptor incapable of binding of TSH neutralizes the action of thyroid-stimulating antibodies from Graves’ patients. Mol Endocrinol 139:671–676
  15. Rapoport B, McLachlan SM, Kakinuma A, Chazenbalk GD 1996 Critical relationship between autoantibody recognition and thyrotropin receptor maturation as reflected in the acquisition of complex carbohydrate. J Clin Endocrinol Metab 81:2525–2533[Abstract]
  16. Seetharamaiah GS, Dallas JS, Patibandla SA, Thotakura NR, Prabhakar BS 1997 Requirement of glycosylation of the human thyrotropin receptor ectodomain for its reactivity with autoantibodies in patients’ sera. J Immunol 158:2798–2804[Abstract]
  17. Chazenbalk GD, Rapoport R 1995 Expression of the extracellular domain of the thyrotropin receptor in the baculovirus system using a promoter active earlier than the polyhedrin promoter. J Biol Chem 270:1543–1549[Abstract/Free Full Text]
  18. Kajava AV, Vassart G, Wodak SJ 1995 Modeling of the three-dimensional structure of proteins with the typical leucine-rich repeats. Structure 3:867–877[Medline]
  19. Patibandla SA, Seetharamaiah GS, Dallas JS, Thotakura NR, Peake RL, Prabhakar BS 1997 Differential reactivities of recombinant glycosylated ectodomains of mouse and human thyrotropin receptors with patient autoantibodies. Endocrinology 138:1559–1566[Abstract/Free Full Text]
  20. Chazenbalk GD, Jaume JC, McLachlan SM, Rapoport B 1997 Engineering the human thyrotropin receptor ectodomain from a non-secreted form to a secreted, highly immunoreactive glycoprotein that neutralizes autoantibodies in Graves’ patients’ sera. J Biol Chem 272:18959–18965[Abstract/Free Full Text]
  21. Chazenbalk GD, Wang Y, Guo J, et al. 1999 A mouse monoclonal antibody to a thyrotropin receptor ectodomain variant provides insight into the exquisite antigenic conformational requirement, epitopes and in vivo concentration of human autoantibodies. J Clin Endocrinol Metab 84:702–710[Abstract/Free Full Text]
  22. Seetharamaiah GS, Zhuang J, Huang J, et al. 1999 Selective binding of thyrotropin receptor autoantibodies to recombinant extracellular domain of thyrotropin/lutropin-chrionic gonadotropin receptor chimeric proteins. Thyroid 9:879–885[Medline]
  23. Tahara K, Ban T, Minegishi T, Kohn LD 1991 Immunoglobulins from Graves’ disease patients interact with different sites on TSH receptor/LH-CG receptor chimeras than either TSH or immunoglobulins from idiopathic myxedema patients. Biochem Biophys Res Commun 179:70–77[CrossRef][Medline]
  24. Kim WB, Cho BY, Park HY, et al. 1996 Epitopes for thyroid stimulating antibodies in Graves’ sera: a possible link of heterogeneity to differences in response to antithyroid drug treatment. J Clin Endocrinol Metab 81:1758–1767[Abstract]
  25. Grasso YZ, Kim MR, Faiman C, Kohn LD, Tahara K, Gupta MK 1999 Epitope heterogenety of thyrotropin receptor-blocking antibodies in Graves’ patients as detected with wild-type versus chimeric thyrotropin receptors. Thyroid 9:531–537[Medline]
  26. Jaume JC, Frummel MF, Wiersinga WM, McLachlan SM, Rapoport B 1993 Thyrotropin receptor autoantibodies recognizing two different epitopes on the TSH receptor: lack of relationship to patient age, sex and ophthalmopathy. Thyroid 3:291–295[Medline]
  27. Nagayama Y, Wadsworth HL, Russo D, Chazenbalk GD, Rapoport B 1991 Binding domains of stimulatory and inhibitory thyrotropin (TSH) receptor autoantibodies determined with chimeric TSH-lutropin/chorionic gonadotropin receptors. 88:336–340
  28. Watanabe Y, Tahara K, Hirai A, Tada H, Kohn LD, Amino N 1997 Subtypes of anti-TSH receptor antibodies classified by various assays using CHO cells expressing wild-type or chimeric human TSH receptor. Thyroid 7:13–19[Medline]
  29. Tahara K, Ishikawa N, Yamamoto K, et al. 1997 Epitopes for thyroid stimulating and blocking autoantibodies on the extracellular domain of the human thyrotropin receptor. Thyroid 7:867–877[Medline]
  30. Kim WB, Chung HK, Park YJ, et al. 2000 The prevalence and clinical significance of blocking thyrotropin receptor antibodies in untreated hyperthyroid Graves’ disease. Thyroid 10:579–586[Medline]
  31. McCarron RM, Fallis RB, McFarlin DE 1990 Alterations in T cell antigen specificity and class II restriction during the course of chronic relapsing experimental allergic encephalomyelitis. J Neuroimmunol 29:73–79[CrossRef][Medline]
  32. Lehmann PV, Forsthuber T, Miller A, Sercarz EE 1992 Spreading of T cell autoimmunity to cryptic determinants of an autoantigen. Nature 358:155–157[CrossRef][Medline]
  33. Tuohy VK, Yu M, Yin L, et al. 1998 The epitope spreading cascade during progression of experimental autoimmune encephalomyelitis and multiple sclerosis. Immunol Rev 164:93–100[CrossRef][Medline]
  34. McCluskey J, Farris AD, Keech CL, et al. 1998 Determinant spreading: lessons from animal models and human disease. Immunol Rev 164:209–229[CrossRef][Medline]
  35. Patibandla SA, Fan JL, Prabhakar BS, Seetharamaiah GS 1999 Comparison of immune responses to extracellular domains of mouse and human thyrotropin receptor. J Autoimmun 13:205–213[CrossRef][Medline]
  36. Seetharamaiah GS, Dallas JS, Prabhakar BS 1999 Glycosylated ectodomain of the human thyrotropin receptor induces antibodies capable of reacting with multiple blocking epitopes. Autoimmunity 29:21–31[Medline]
  37. Fan JL, Peterson JW, Prabhakr BS 1999 Adjuvant effects of cholera toxin ß subunit on immune response to recombinant thyrotropin receptor in mice. J Autoimmun 14:43–52
  38. Wagle NM, Dallas JS, Seetharamaiah GS, et al. 1994 induction of hyperthyroxinemia in BALB/c but not several other strains of mice. Autoimmunity 18:103–112[Medline]
  39. Kaithamana S, Fan JL, Osuga Y, Shan-Guang L, Prabhakar BS 1999 Induction of experimental autoimmune Graves’ disease in BALB/C mice. J Immunol 163:5157–5164[Abstract/Free Full Text]



This article has been cited by other articles:


Home page
 J. Clin. Endocrinol. Metab.Home page
J. Van Sande, M. J. Costa, C. Massart, S. Swillens, S. Costagliola, J. Orgiazzi, and J. E. Dumont
Kinetics of Thyrotropin-Stimulating Hormone (TSH) and Thyroid-Stimulating Antibody Binding and Action on the TSH Receptor in Intact TSH Receptor-Expressing CHO Cells
J. Clin. Endocrinol. Metab., November 1, 2003; 88(11): 5366 - 5374.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Submit a related Letter to the Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Cundiff, J. G.
Right arrow Articles by Prabhakar, B. S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Cundiff, J. G.
Right arrow Articles by Prabhakar, B. S.

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals